CPM Webinar: The EU Unified Patent Court is opening: To be in or to opt-out?
December 7, 2022 1:00 PM to 2:00 PM
Free for AIPLA Members !
April 1st 2023 is the current target date for the EU Unified Patent Court (UPC) to open and begin receiving cases. The UPC will have parallel territorial jurisdiction with national patent courts for all existing European Patents unless the patent owners “opt-out” of UPC jurisdiction. Learn the implications of the new system, how to opt-out, and some considerations in deciding whether to opt-out; and receive strategic tips for handling your European Patent portfolio.
Presented by: John Pegram, Fish & Richardson, PC and Sofia Santoro, Società Italiana Brevetti. Moderated by: Adrian Eggen, Philip Morris Products
News
-
AIPLA Comments to the Copyright Office on Alternative Fee Structures for Registration
July 6, 2026
Alexandria, VA. June 24, 2026 – The American Intellectual Property Law Association (AIPLA) submitted comments on the U.S. Copyright Office's Notice of Inquiry regarding alternative copyright registration fee structures. -
AIPLA Comments to the Copyright Office on Group Registration of Updates to a News Website
July 6, 2026
Alexandria, VA. June 29, 2026 – The American Intellectual Property Law Association (AIPLA) submitted comments supporting the U.S. Copyright Office's proposed expansion of eligibility for group registration of updates to news websites by removing restrictions that exclude subject-specific publications. -
AIPLA Submits Comments on the World Intellectual Property Organization Riyadh Design Law Treaty
June 24, 2026
Alexandria, VA. June 11, 2026 – The American Intellectual Property Law Association (AIPLA) submitted comments on the World Intellectual Property Organization Riyadh Design Law Treaty. -
.png?sfvrsn=143e8f56_1 "supreme court")
AIPLA Files Amicus Brief in Arbutus Biopharma Corp. v. Moderna, Inc.
June 22, 2026
Arlington, VA. June 5, 2026 – The American Intellectual Property Law Association (AIPLA) filed an amicus brief in Arbutus Biopharma Corp. v. Modernatx, Inc. -
Supreme Court Issues Unanimous Decision in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.
June 4, 2026
On June 4, 2026, the Supreme Court issued a unanimous decision in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. While the Court reaffirmed existing law on pleading standards, it reversed the Federal Circuit’s decision that had focused on how relevant statements could be understood by medical providers as instructions to infringe. The amicus brief filed by AIPLA on March 27, 2026, advocated for affirmance and cautioned the Court not to change the patent infringement pleading standard or adopt any categorical exemption from inducement for a particular industry.